Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425321 | 0.88 | CASP6 (0.60) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL20757 | 0.82 | PDK1 (0.68) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL1483517 | 0.82 | CASP6 (0.66) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL30481076 | 0.82 | CASP6 (0.66) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL6341472 | 0.82 | CASP6 (0.66) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL1251308 | 0.81 | CASP6 (0.64) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL18833531 | 0.81 | CASP6 (0.64) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL8092214 | 0.81 | CASP6 (0.64) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL40979 | 0.81 | CASP6 (0.64) | HCAR3CASP6TSHRLMNAAPEX1 | |
| SCHEMBL2292095 | 0.81 | CASP6 (0.64) | HCAR3CASP6TSHRLMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2016029136-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | L3MBTL3, AFG3L2, AMPD3 | HCAR3 1231/4885CASP6 1568/4885TSHR 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.